Cases & Deals

Rain Therapeutics expands patent portfolio related to clinical stage cancer therapies

Clients Rain Therapeutics Inc.

Jones Day advised Rain Therapeutics Inc. in connection with global patent portfolio development related to a hypoxia-activated prodrug of a potent pan-HER inhibitor, Tarloxotinib (Tarlox), for the treatment of non-small cell lung cancer in patients with EGFR and HER exon 20 insertion mutations.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.